Audentes Therapeutics Inc. (BOLD) announced positive interim results from the first dose cohort of its Phase 1/2 clinical trial of AT132 Thursday morning.
Audentes Therapeutics has been rising steadily since the open of trade Thursday and is now up 4.21 at $39.74. The stock has climbed to its third consecutive new high for the year.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News